BR0016651A - Composto, composição farmacêutica, método de tratamento ou prevenção, e, uso de um composto - Google Patents

Composto, composição farmacêutica, método de tratamento ou prevenção, e, uso de um composto

Info

Publication number
BR0016651A
BR0016651A BR0016651-0A BR0016651A BR0016651A BR 0016651 A BR0016651 A BR 0016651A BR 0016651 A BR0016651 A BR 0016651A BR 0016651 A BR0016651 A BR 0016651A
Authority
BR
Brazil
Prior art keywords
alkyl
aryl
halogen
alkoxy
heteroaryl
Prior art date
Application number
BR0016651-0A
Other languages
English (en)
Inventor
Denis Deschenes
Daniel Dube
Michel Gallant
Yves Girard
Patrick Lacombe
Dwight Macdonald
Anthony Mastracchio
Helene Perrier
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of BR0016651A publication Critical patent/BR0016651A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA MéTODO DE TRATAMENTO OU PREVENçãO, E, USO DE UM COMPOSTO". Novas 8-arilquinolinas substituídas representadas pela Fórmula (I), ou um sal farmaceuticamente aceitável destas, em que S~ 1~, S~ 2~ e S~ 3 são independentemente H, -OH; halogênio, alquila C~ 1~-C~ 6~, -NO~ 2~, -CN ou alcóxi C~ 1~-C~ 6~, em que os grupos de alquila e alcóxi são opcionalmente substituídos com 1 a 5 substituintes; em que cada substituinte é independentemente um halogênio ou OH; R~ 1~ é um H, OH, halogênio, carbonila ou grupo de alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~, alquenila C~ 1~-C~ 6~, alcóxi C~ 1~-C~ 6~, arila, heteroarila, -CN, heterocicloalquila C~ 3~-C~ 6~, -amino, alquilamino C~ 1~-C~ 6~, -(alquila C~ 1~-C~ 6~)(alquila C~ 1~-C~ 6~)amino, alquil C~ 1~C~ 6~(óxi)alquila C~ 1~-C~ 6~, -C(O)NH(arila), -C(O)NH(heteroarila), -SO~ n~NH(arila), -SO~ nNH(arila), -SO~ n~NH(heteroarila), -SO~ n~NH(alquila C~ 1~-C~ 6~), -C(O)N(alquila C~ 0~-C~ 6~) (alquila C~ 0~-C~ 6~), -NH-SO~ n~-(alquila C~ 1~-C~ 6~), -SO~ n~(alquila C~ 1~-C~ 6~), -(alquila C~ 1~-C~ 6~)-O-C(CN)-dialquilamino, ou -(alquila C~ 1~-C~ 6~)SO~ n~-(alquila C~ 1~-C~ 6~), em que qualquer um dos grupos é opcionalmente substituído com 1 a 5 substituintes; em que cada substituinte é independentemente um halogênio, -OH, -CN, alquila C~ 1~-C~ 6~, -cicloalquila C~ 3~C~ 6~, -C(O)(heterociclo-alquila C~ 3~-C~ 6~), -C(O)-O-(alquila C~ 0~-C~ 6~), -C(O)-arilóxi, alcóxi C~ 1~-C~ 6~, -(alquila C~ 0~-C~ 6~)(alquila C~ 0~-C~ 6~)amino, cicloalcóxi, acila, acilóxi, -cicloalquila C~ 3~-C~ 6~, heterocicloalquila C~ 3~-C~ 6~, arila, heteroarila, carbonila, carbamoíla ou -SO~ n~-(alquila C~ 1~-C~ 6~); A é CH, C-éster ou C-R~ 4~; R~ 2~ e R~ 3~ independentemente são um grupo arila, heteroafila, H, halogênio, -CN, -alquila, C~ 1~-C~ 6~, heterocicloalquila C~ 3~-C~ 6~, -alcóxi C~ 1~-C~ 6~, carbonila, carbamoíla, -C(O)OH, -(alquila C~ 1~-C~ 6~)-SO~ n~-(alquila C~ 1~-C~ 6~), -C(O)N(alquila C~ 0~C~ 6~)(alquila C~ 0~-C~ 6~), ou alquilacilamino C~ 1~-C~ 6~, em que qualquer um dos grupos é opcionalmente substituído com 1 a 5 substituintes, em que cada substituinte é independentemente uma arila, heteroarila, halogênio, -NO~ 2~, -C(O)OH, carbonila, -CN, alquila C~ 1~-C~ 6~, -SO~ n~-(alquila C~ 1~-C~ 6~), -SO~ n~-(arila), arilóxi, heteroarilóxi, alcóxi C~ 1~-C~ 6~, N-óxido, -C(O) heterocicloalqilia C~ 3~-C~ 6~, -NHcicloalquila C~ 3~-C~ 6~, amino, -OH ou grupo substituinte de -(alquila C~ 0~C~ 6~)(alquila C~ 0~-C~ 6~)amino, -C(O)-N(alquila C~ 0~-C~ 6~)(alquila C~ 0~-C~ 6~), em que cada grupo substituinte independentemente é opcionalmente substituído com -OH, alcóxi C~ 1~-C~ 6~, alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~, arilóxi, -C(O)OH, C(O)O(alquila C~ 1~-C~ 6~), halogênio, -NO~ 2~, -CN, -SO~ n~-(alquila C~ 1~-C~ 6~), ou -C(O)N(alquila C~ 0~-C~ 6~)(alquila C~ 0~-C~ 6~); um de R~ 2~ e R~ 3~ deve ser uma arila ou heterarila, opcionalmente substituída; quando R~ 2~ e R~ 3~ forem ambos uma arila ou heteroarila, então R~ 2~ e R~ 3~ podem ser opcionalmente conectados por uma ponte tio, óxi ou (alquila C~ 1~-C~ 4~) para formar um sistema de três anéis fundidos; são inibidores de PDE4.
BR0016651-0A 1999-12-22 2000-12-20 Composto, composição farmacêutica, método de tratamento ou prevenção, e, uso de um composto BR0016651A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17152299P 1999-12-22 1999-12-22
PCT/CA2000/001559 WO2001046151A1 (en) 1999-12-22 2000-12-20 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Publications (1)

Publication Number Publication Date
BR0016651A true BR0016651A (pt) 2002-09-10

Family

ID=22624050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016651-0A BR0016651A (pt) 1999-12-22 2000-12-20 Composto, composição farmacêutica, método de tratamento ou prevenção, e, uso de um composto

Country Status (32)

Country Link
EP (1) EP1244628A1 (pt)
JP (1) JP3782011B2 (pt)
KR (1) KR20020082839A (pt)
CN (1) CN1221534C (pt)
AR (1) AR029214A1 (pt)
AU (1) AU778531B2 (pt)
BG (1) BG65403B1 (pt)
BR (1) BR0016651A (pt)
CA (1) CA2393749C (pt)
CO (1) CO5261613A1 (pt)
CZ (1) CZ20022171A3 (pt)
DZ (1) DZ3244A1 (pt)
EA (1) EA004747B1 (pt)
EE (1) EE200200342A (pt)
GE (1) GEP20053626B (pt)
HK (1) HK1057560A1 (pt)
HR (1) HRP20020545A2 (pt)
HU (1) HUP0203896A3 (pt)
IL (1) IL150114A0 (pt)
IS (1) IS6413A (pt)
MX (1) MXPA02006329A (pt)
MY (1) MY134008A (pt)
NO (1) NO20023013L (pt)
NZ (1) NZ520258A (pt)
PE (1) PE20010989A1 (pt)
PL (1) PL355752A1 (pt)
SK (1) SK8972002A3 (pt)
TW (1) TWI280240B (pt)
UA (1) UA74815C2 (pt)
WO (1) WO2001046151A1 (pt)
YU (1) YU47102A (pt)
ZA (1) ZA200204862B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
CN1211383C (zh) * 2000-12-20 2005-07-20 麦克公司 制备取代的8－芳基喹啉鎓苯磺酸盐的方法
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
DE60204463T2 (de) * 2001-06-27 2006-05-18 Merck Frosst Canada & Co, Kirkland Substituierte 8-Arylchinoline als PDE4-Hemmer
US7009055B2 (en) * 2001-07-24 2006-03-07 Merck & Co., Inc. Preparation of Sulfonyl quinoline
ATE349243T1 (de) * 2001-09-19 2007-01-15 Altana Pharma Ag Kombination von einem pde-hemmer und eines leukotrien rezeptor antagonisten
ATE432261T1 (de) * 2002-03-18 2009-06-15 Merck Frosst Canada Ltd Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin
BRPI0408005A (pt) * 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
AU2005226741A1 (en) * 2004-03-25 2005-10-06 Synta Pharmaceuticals Corp. Acrylonitrile derivatives for inflammation and immune-related uses
WO2006123954A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
PL2363130T3 (pl) 2006-07-05 2014-09-30 Astrazeneca Ab Kombinacja inhibitorów reduktazy HMG-CoA atorwastatyny i symwastatyny z inhibitorem fosfodiesterazy, takim jak roflumilast do leczenia zapalnych chorób płuc
US7745646B2 (en) * 2006-07-07 2010-06-29 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of PDE4
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬

Also Published As

Publication number Publication date
ZA200204862B (en) 2003-03-17
DZ3244A1 (fr) 2001-06-28
EA004747B1 (ru) 2004-08-26
HUP0203896A2 (hu) 2003-04-28
NO20023013D0 (no) 2002-06-21
CN1434801A (zh) 2003-08-06
AR029214A1 (es) 2003-06-18
BG106840A (en) 2003-01-31
YU47102A (sh) 2005-06-10
EP1244628A1 (en) 2002-10-02
TWI280240B (en) 2007-05-01
GEP20053626B (en) 2005-10-10
CO5261613A1 (es) 2003-03-31
PE20010989A1 (es) 2001-10-01
CA2393749A1 (en) 2001-06-28
NZ520258A (en) 2004-05-28
JP2003531112A (ja) 2003-10-21
AU778531B2 (en) 2004-12-09
MXPA02006329A (es) 2004-05-14
CA2393749C (en) 2008-06-17
HUP0203896A3 (en) 2003-05-28
JP3782011B2 (ja) 2006-06-07
CZ20022171A3 (cs) 2002-11-13
MY134008A (en) 2007-11-30
PL355752A1 (en) 2004-05-17
AU2336201A (en) 2001-07-03
WO2001046151A1 (en) 2001-06-28
IS6413A (is) 2002-06-11
EA200200702A1 (ru) 2003-02-27
IL150114A0 (en) 2002-12-01
UA74815C2 (en) 2006-02-15
BG65403B1 (bg) 2008-06-30
HK1057560A1 (en) 2004-04-08
NO20023013L (no) 2002-08-22
CN1221534C (zh) 2005-10-05
SK8972002A3 (en) 2002-11-06
EE200200342A (et) 2003-06-16
KR20020082839A (ko) 2002-10-31
HRP20020545A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
BR0016651A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção, e, uso de um composto
DE69310501D1 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
BR9807068A (pt) Compostos de quinolina e quinazolina úteis em terapêutica, particularmente no tratamento de hiperplasia prostática benigna
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
CA2444634A1 (en) Spiropyrazole compounds
DK1092716T3 (da) Benzothiophenderivater, benzofuranderivater og indolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske tilberedninger indeholdende disse
KR890006650A (ko) 테트라하이드로-푸로 및 -티에노［2,3-c］피리딘, 약제학적 제제로서의 이의 용도 및 이의 제조방법
DE69621421D1 (de) Erythromycin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69710319D1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
EP1566379A4 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
ATE29255T1 (de) Succinimid-derivate und deren herstellung.
DK323688D0 (da) Pyridinforbindelser
PT959906E (pt) Corantes funcionais delta1,6 biciclo¬4.4.0| para intensificacao do contraste em imagiologia optica
DE3853577D1 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
DE68908481D1 (de) In 2-stellung substituierte cumaranderivate.
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BRPI0510078A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição, distúrbios ou doença tratável com androgênios, de tratamento de uma condição, distúrbio ou doença relacionada com receptor de androgênio e de contracepção masculina
KR970707107A (ko) 산화질소 합성효소 억제제로서 유용한 아미노테트라졸 유도체(aminotetrazole derivatives useful as nitric oxide synthase inhibtors)
KR890011851A (ko) 이소 키놀린 유도체, 그 제조방법 및 사용방법
KR940014385A (ko) 신규의 퀴나졸린 유도체 및 그의 제조방법
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
ATE247103T1 (de) Chinolin- und benzimidazolderivate als bradykinin agonisten
BR0311315A (pt) Sulfonas aromáticas e sua utilização médica
AR035514A1 (es) Sales farmaceuticamente aceptables de inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida, composiciones farmaceuticas y su uso en la preparacion de medicamentos
BR9801506A (pt) Compostos de quinolina e quinazolina úteis em terapia.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK FROSST CANADA LTD. (CA)

Free format text: TRANSFERIDO DE: MERCK FROSST CANADA AND CO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.